Low-Dose Human Chorionic Gonadotropin Maintains Intratesticular Testosterone in Normal Men with Testosterone-Induced Gonadotropin Suppression

This is the Coviello et al. dose-response trial of low-dose human chorionic gonadotropin (hCG) in men with experimentally induced gonadotropin suppression — the foundational paper for hCG's role as the testicular-function-preserving adjunct to testosterone replacement therapy. The trial is small (n=29) but methodologically meticulous: it characterizes the dose-response relationship between hCG and intratesticular testosterone (ITT) — the variable that proximally supports spermatogenesis — under conditions of complete pituitary LH suppression by exogenous testosterone, the same suppression state that occurs in standard clinical TRT.

The design was a four-arm parallel-group trial in healthy young men. All twenty-nine participants received testosterone enanthate 200 mg intramuscularly weekly to induce gonadotropin suppression, a regimen that reliably drives LH to undetectable levels and suppresses Leydig-cell steroidogenesis within several weeks. Concurrently, participants were randomized to one of four hCG arms: placebo, 125 IU every other day, 250 IU every other day, or 500 IU every other day. Intratesticular testosterone was the primary endpoint, measured by testicular fluid aspiration before treatment initiation and at the conclusion of the three-week treatment period — the unusual primary endpoint for which this trial is most cited, since ITT measurement requires direct testicular sampling and is rarely characterized in clinical work.

The dose-response result is clean. Intratesticular testosterone increased linearly with hCG dose. In the placebo arm, ITT fell by approximately 94% from baseline — characterizing the magnitude of testicular shutdown under exogenous testosterone alone. In the 125 IU every-other-day arm, ITT was suppressed approximately 75% relative to baseline. In the 250 IU every-other-day arm, ITT was suppressed approximately 7% relative to baseline — essentially restored to the lower end of the normal range. In the 500 IU every-other-day arm, ITT was 26% above baseline despite the complete suppression of pituitary LH. The 500 IU dose, in other words, produced supraphysiologic intratesticular testosterone in the setting of full pituitary suppression — the operating regime in which spermatogenesis is mechanistically supported even though circulating LH is undetectable.

The clinical translation of the Coviello result is the basis for the Hsieh et al. 2013 protocol (hCG 500 IU intramuscular every other day plus standard TRT) that became the standard fertility-preserving TRT regimen, and is the operational reference behind the hCG peptide page and the dose-logic anchoring the andropause-and-peptides dossier. The mechanistic insight Coviello supplies — that hCG dose-response on ITT is essentially linear, that the threshold for full ITT restoration is in the 125–250 IU every-other-day range, and that supraphysiologic ITT can be achieved at 500 IU every-other-day — is the empirical floor under all subsequent hCG-during-TRT clinical practice.

For the TRT discontinuation playbook, Coviello informs the parallel question: men exiting TRT need testicular function restoration, and the dose-response data here characterizes the testicular axis's responsiveness to LH-mimetic stimulation under suppression — directly relevant to restart protocols. The men in Coviello had healthy baseline testicular function before the experimental gonadotropin suppression; men with long-duration prior TRT have potentially down-regulated Leydig-cell apparatus, and the dose-response observed in Coviello may not translate one-to-one. The directionality and threshold logic does translate; the absolute numerical recovery probably does not.